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Abstract
Probiotics have been used as alternative prevention and therapy modalities in intestinal inflammatory disorders including
inflammatory bowel diseases (IBD) and necrotizing enterocolitis (NEC). Pathophysiology of IBD and NEC includes the
production of diverse lipid mediators, including platelet-activating factor (PAF) that mediate inflammatory responses in the
disease. PAF is known to activate NF-kB, however, the mechanisms of PAF-induced inflammation are not fully defined. We
have recently described a novel PAF-triggered pathway of NF-kB activation and IL-8 production in intestinal epithelial cells
(IECs), requiring the pivotal role of the adaptor protein Bcl10 and its interactions with CARMA3 and MALT1. The current
studies examined the potential role of the probiotic Lactobacillus acidophilus in reversing the PAF-induced, Bcl10-dependent
NF-kB activation and IL-8 production in IECs. PAF treatment (5 mM624 h) of NCM460 and Caco-2 cells significantly increased
nuclear p65 NF-kB levels and IL-8 secretion (2-3-fold, P,0.05), compared to control, which were blocked by pretreatment of
the cells for 6 h with L. acidophilus (LA) or its culture supernatant (CS), followed by continued treatments with PAF for 24 h.
LA-CS also attenuated PAF-induced increase in Bcl10 mRNA and protein levels and Bcl10 promoter activity. LA-CS did not
alter PAF-induced interaction of Bcl10 with CARMA3, but attenuated Bcl10 interaction with MALT1 and also PAF-induced
ubiquitination of IKKc. Efficacy of bacteria-free CS of LA in counteracting PAF-induced inflammatory cascade suggests that
soluble factor(s) in the CS of LA mediate these effects. These results define a novel mechanism by which probiotics
counteract PAF-induced inflammation in IECs.
Citation: Borthakur A, Bhattacharyya S, Kumar A, Anbazhagan AN, Tobacman JK, et al. (2013) Lactobacillus acidophilus Alleviates Platelet-Activating Factor-
Induced Inflammatory Responses in Human Intestinal Epithelial Cells. PLoS ONE 8(10): e75664. doi:10.1371/journal.pone.0075664
Editor: Rajvir Dahiya, UCSF/VA Medical Center, United States of America
Received July 29, 2013; Accepted August 16, 2013; Published October 9, 2013
Copyright:  2013 Borthakur et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK): DK-54016
(PKD), DK-81858 (PKD), DK-92441 (PKD); Bill & Melinda Gates Foundation: OPP1058288 (AB) and Department of Veteran Affairs (PKD). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: alipb@uic.edu
Introduction
Recent clinical and experimental outcomes have shown that
intestinal luminal microbiota play pivotal role in the pathogenesis
of inflammatory bowel diseases (IBD) and necrotizing enterocolitis
(NEC) [1–4]. Therefore, modifying gut flora composition using
probiotics has been emerging as a promising strategy to alleviate
mucosal inflammation in these diseases [3,5,6]. Probiotic bacteria
including Lactobacilli have been shown to interact with cells of the
mucosal surface and locally modulate the production and/or
activity of inflammatory mediators [7]. In this regard, platelet
activating factor (PAF), a potent bioactive phospholipid known to
cause intestinal injury [8], has been implicated in the pathogenesis
of IBD [9,10] and NEC [11,12]. Elevated PAF levels have been
reported in tissues and/or serum in response to pathogen
infection, and in patients with Crohn’s disease, ulcerative colitis,
and NEC, that correlated with disease severity [9,10,12,13]. PAF
acts by binding to and activating G-protein coupled PAF receptors
(PAF-R). Highest concentrations of PAF-R expression have been
reported in intestinal epithelium [14]. PAF is known to activate
NF-kB, a key transcriptional regulator of the expression of
proinflammatory cytokines and many immunoregulatory mole-
cules in response to inflammatory stimuli [15–17] and microbial
infection [18]. However, the early receptor-mediated signaling
events that initiate these responses are not completely defined.
NF-kB activity is tightly regulated by interaction with inhibitory
proteins, IkBs, which sequester NF-kB in cytoplasm. Upon
stimulation, IkB is phosphorylated by the NF-kB-activating IkB
kinase (IKK) complex, ubiquitinated, and degraded by the 26S
proteasome complex, thereby releasing NF-kB to translocate into
the nucleus and initiate specific target gene transcription [19].
Studies during the past two decades have revealed tissue-specific
and stimulus-specific roles of many scaffold proteins in linking
different receptors to the IKK complex [20,21]. Among those, a
family of caspase recruitment domain (CARD)-containing scaffold
proteins, known as CARD- and membrane-associated guanylate
kinase-like domain-containing protein (CARMA) plays critical
roles in recruitment and activation of IKK. Bcl10 and MALT1
physically interact to activate NF-kB whereas CARMA proteins
function as upstream regulators of Bcl10 and MALT1 in response
to various stimuli in different tissues. Together, these three
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proteins constitute the CARMA/Bcl10/MALT1 (CBM) signalo-
some, which plays a critical role in regulating NF-kB activation
both in normal physiology as well as in various pathophysiological
conditions [22]. Originally described in immune cells [23], this
pathway has been shown to mediate inflammatory responses in
myeloid and epithelial cell types [22], including intestinal epithelial
cells [24–26]. Importantly, we have recently reported a novel
inflammatory pathway induced by PAF to activate NF-kB and
produce IL-8 in human intestinal epithelial cells. This NF-kB-
activating cascade involved upregulation of Bcl10 expression and
its increased interactions with CARMA3 and MALT1 [24].
Multiple studies have shown the role of probiotic bacteria in
ameliorating intestinal inflammation via inhibition of NF-kB
activity [27,28]. However, despite known involvement of PAF as
an inflammatory mediator in IBD and NEC, there are no studies
testing the efficacy of probiotics or probiotic-derived molecules in
counteracting pro-inflammatory effects of PAF in diseases. Since
PAF-induced NF-kB activation via CARMA3-Bcl10-MALT1
signalosome could highlight important targets for intervention,
we investigated the effects of probiotic Lactobacilli in counteracting
PAF-induced inflammation and explored the underlying mecha-
nisms.
Results
L. acidophilus blocks PAF-induced NF-kB activation and
IL-8 production in human intestinal epithelial cells
We have previously shown that PAF has a specific direct effect
on NF-kB activation and IL-8 secretion in human colonic
NCM460 and Caco-2 cells [24]. In this study, we examined the
efficacy of few important Lactobacillus species in blocking the effects
of PAF on NF-kB activation. During NF-kB activation, inhibitory
IkB proteins are phosphorylated by the IKK signalosome, thereby
releasing NF-kB for nuclear translocation to activate target genes
[19,20]. Therefore, we used oligonucleotide-based ELISA and
immunoblotting to measure NF-kB (p65) in the nuclear fractions
isolated from control and treated NCM460/Caco-2 cells.
NCM460 cells were pre-incubated for 6 h with one of the
following Lactobacillus species: L. acidophilus, L. rhamnosus, L.
plantarum and L. casei followed by 24 h further incubation with or
without 5 mM PAF. NF-kB activation was assessed by measuring
p65 levels in the nuclear extracts from NCM460 cells, control and
different treatment groups, utilizing oligonucleotide probe-based
ELISA. As shown in Figure 1A, the two species, L. acidophilus (LA)
and L. rhamnosus (LR) significantly attenuated the PAF-induced
increase in nuclear p65, whereas the other two species were
ineffective. We, therefore, utilized only one species, LA, for all
subsequent studies. We next examined the effects of heat-killed LA
or its conditioned culture supernatant (CS) on nuclear p65 levels.
Heat-killed LA failed to attenuate PAF-induced increase in nuclear
p65, whereas, similar to live LA, its CS (diluted 1:10 in DMEM/
F12) was equally effective in attenuating the PAF effects on nuclear
p65 (Figure 1B). A dose-dilution response of CS was initially
performed and 1:10 dilution was chosen to obtain the optimal
effect and at the same time to avoid adverse effects of long-term
incubation on cell viability as observed with lesser dilutions (1:2 or
1:5). These results indicate that LA effects on PAF-induced NF-kB
activation are mediated by secreted soluble factor(s) in the CS.
Therefore, for all subsequent experiments we used LA-CS instead
of live LA for treatment of cells. Nuclear p65 levels as assessed by
immunoblotting are shown in Figure 2A. PAF increased nuclear
p65 in both NCM460 and Caco-2 cells, whereas LA-CS blocked
the PAF effects on nuclear p65. We also measured NF-kB activity
by transfecting Caco-2 cells with the NF-kB transcription reporter
vector p-NF-kB-Luc (BD Biosciences). This vector contains NF-kB
consensus sequence located upstream of the firefly luciferase
reporter gene. After 16 h of stimulation, PAF (5 mM) activated NF-
kB-dependent reporter gene in Caco-2 cells (,2-fold compared to
control). This increase was significantly attenuated in cells
preincubated with LA-CS for 6 h, followed by continued
treatments along with PAF. (Figure 2B).
L. acidophilus attenuates PAF-induced I-kB
phosphorylation
We also measured phospho-IkB utilizing an ELISA-based
method to assess the levels in response to PAF and/or LA-CS
treatments. LA-CS significantly attenuated phospho-IkB levels
compared to control and also blocked the PAF-induced increase in
phospho-IkB levels in NCM460 cells (Figure 3A).
L. acidophilus blocks PAF-induced IL-8 production
We next tested whether the PAF-induced increase in IL-8 in the
spent media, as reported earlier [24], was reversed by LA-CS
treatments. LA-CS alone did not affect IL-8 levels in the spent
media of NCM460 cells, as measured by ELISA. However, pre-
and continued incubation of the cells with LA-CS significantly
attenuated the PAF-induced IL-8 in the spent media (Figure 3B)
Figure 1. L. acidophilus and its culture supernatant counteract
PAF-induced NF-kB activation in IECs. (A) Nuclear extracts of
control or PAF 6 L. acidophilus (LA), L. rhamnosus (LR), L. plantarum (LP)
or L. casei (LC)-treated NCM460 cells for 24 h were utilized to measure
p65 levels by oligonucleotide-based ELISA (n = 5, *P,0.05); (B) p65
levels in the nuclear extracts from control or PAF 6 L. acidophilus
culture supernatant (CS) or heat-killed LA-treated NCM460 cells (n = 3,
*P,0.05).
doi:10.1371/journal.pone.0075664.g001
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LA-CS attenuated PAF-induced increase in Bcl10 mRNA
and protein expression, and Bcl10 promoter activity
Our previous studies showed that PAF treatments caused a
dose-dependent increase in Bcl10 protein expression, and that
Bcl10 was required for PAF-induced NF-kB activation and IL-8
secretion [24]. Therefore, we sought to investigate whether LA-
CS, which blocked PAF-induced NF-kB activation and IL-8
production, also regulates expression of Bcl10. LA-CS alone had
no effects on Bcl10 mRNA levels (Figure 4A), Bcl10 protein, as
measured by ELISA (Figure 4B) and immunoblotting (Figure
4C) in NCM460 cells, and Bcl10 promoter activity (Figure 4D) in
Caco-2 cells. However, pre-treatment of the cells with LA-CS
significantly attenuated the PAF-induced increase in Bcl10 mRNA
and protein expression and Bcl10 promoter activity.
Probiotic supernatants reduced PAF-induced Bcl10-
MALT1 interaction and ubiquitination of IKKc
Recent reports from our laboratory and others [22,24–26]
showed that Bcl10-dependent inflammatory pathways in nonim-
mune cells involve the CARMA-3/Bcl10/MALT1 signalosome
complex. Our previous studies also showed that PAF increased
interaction of Bcl10 with CARMA3 and MALT1 [24]. Therefore,
we used co-immunoprecipitation studies to examine the effects of
preincubating NCM460 cells with LA-CS on the PAF-induced
interactions of Bcl10-CARMA3-MALT1. LA-CS did not alter
PAF-mediated enhancement of Bcl10-CARMA3 interactions (not
shown), but significantly reduced PAF-induced interaction of
Bcl10 and MALT1 (Figure 5A). Specificity of Bcl10/MALT1 co-
immunoprecipitation was confirmed by incubation of the cell
lysate with isotype specific rabbit IgG instead of anti-Bcl10
antibody that failed to immunoprecipitate MALT1 (not shown).
We next sought to analyze the effects of PAF on ubiquitination
of IKKc, the regulatory subunit of IKK complex, which is
reported to be important in Bcl10-mediated NF-kB activation
[29]. Caco-2 cells were transfected with recombinant constructs,
Myc-tagged IKKc and HA-tagged ubiquitin. Ubiquitinated IKKc
was immunoprecipitated with anti-Myc antibody and probed with
anti-HA antibody in immunoblots to assess ubiquitination. PAF
treatment increased ubiquitination of IKKc (,2-fold), which was
attenuated in cells preincubated with LA-CS prior to PAF
treatments (Figure 5B)
Discussion
Gut bacteria play a key role in inflammatory bowel diseases
(IBD) and necrotizing enterocolitis (NEC) [1–4]. Although much
attention has been focused on the search for a pathogen or inciting
inflammatory bacteria, of equal importance is the search for
beneficial commensal bacteria that normally confer anti-inflam-
matory effects in the gut. Probiotics, a group of gut commensals
that confer health benefits are known to ameliorate inflammation
and has been used in clinical trials and experimental models to
alleviate inflammation in IBD and NEC [30–33]. However, the
nature of the probiotic-derived active components that mediate
their beneficial effects and underlying mechanisms of action has
not been fully elucidated. Pathophysiology of IBD and NEC
involves production of diverse lipid mediators, platelet-activating
factor (PAF) being one of them mediating inflammatory responses
in these diseases [9–11,30]. PAF is produced by the human
intestinal epithelium [14], where it mediates a range of biological
effects such as modulation of ion transport, prostaglandin and
eicosanoid synthesis and apoptosis [34–39]. On the other hand,
PAF has also been shown to trigger inflammatory responses via
NF-kB activation [12,15,38] and cytokine and chemokine gene
Figure 2. L. acidophilus culture supernatant attenuates PAF-induced increase in nuclear p65 and NF-kB reporter activity. (A) p65
levels measured by immunoblotting of nuclear extracts prepared from control or PAF6 LA-CS-treated Caco-2 and NCM460 cells (representative blots
from n= 3); (B) NF-kB reporter activity, expressed as percent of control, in control or PAF 6 LA-CS-treated Caco-2 cells (n = 4, *P,0.05).
doi:10.1371/journal.pone.0075664.g002
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expression in a wide variety of cells [17,40,41]. However, the
signaling events that mediate PAF-induced NF-kB activation are
not completely defined. In this regard, we have recently described
a novel inflammatory pathway induced by PAF to activate NF-kB
and produce IL-8 in NCM460, a cell line derived from normal
human colon, and Caco-2, a transformed human intestinal cell
line [24]. Our studies showed that direct in vitro activation of NF-
kB by PAF in intestinal epithelial cells required Bcl10, an adaptor
protein, and its interactions with CARMA3 and MALT1 [24].
The hallmark of antigen receptor-induced NF-kB activation in
lymphocytes has been shown to be the formation CARMA1-
Bcl10-MALT1 signalosome, which directly or indirectly activates
I-kB kinase (IKK) complex to phosphorylate I-kB proteins thereby
releasing NF-kB for nuclear translocation [23]. In non-immune
cells, however, this pathway utilizes CARMA3, a second member
of the CARMA family having a wider tissue distribution [42].
PAF-induced IkBa phosphorylation, NF-kB activation, and IL-8
production in NCM460 and Caco-2 cells were Bcl10-dependent.
PAF upregulated Bcl10 expression in these cells via transcriptional
mechanisms and enhanced its interactions with CARMA3 and
MALT1 [24]. Since proinflammatory effects of PAF play
prominent roles in the pathogenesis of IBD and NEC, it was of
great interest to investigate the effects of probiotic Lactobacilli in
counteracting PAF-induced NF-kB activation via CARMA3-
Bcl10-MALT1 signalosome and to elucidate the underlying
mechanisms. Our results demonstrated that Lactobacillus acidophilus,
an important gut commensal, counteracted PAF induction of
Bcl10-dependent NF-kB activation and IL-8 production in
intestinal epithelial NCM460 and Caco-2 cells. Earlier we have
shown that this specific strain of L. acidophilus, and more
importantly its conditioned culture supernatant, exhibited pro-
absorptive effects via distinct mechanisms to stimulate intestinal
absorption of NaCl, thereby defining its novel therapeutic
potential to ameliorate diarrhea associated with IBD [43,44].
Interestingly, our current studies also showed that heat-killed LA
failed to attenuate PAF-induced increase in nuclear p65 and
importantly, bacteria-free CS of LA was as effective as live LA in
attenuating the PAF effects on nuclear p65, indicating that LA
effects on PAF-induced NF-kB activation are mediated by secreted
soluble factor(s) in the CS. LA-CS also attenuated basal NF-kB
reporter activity as well as completely blocked PAF-mediated
increase in NF-kB reporter activity. Further, LA-CS not only
attenuated IL-8 secretion and I-kB phosphorylation compared to
control, but also blocked PAF-induced increase in IL-8 secretion
and I-kB phosphorylation. Various earlier studies have shown the
importance of bacteria-secreted soluble factors, cell wall compo-
nents, and bacterial DNA as mediators of the beneficial effects of
bacteria [45–48]. These studies are of great significance for
eliminating the concerns in using live bacteria to treat diseases like
IBD. However, determining the exact chemical nature of the
bacteria-derived factors and elucidating their mechanisms of
action will only help design targeted therapies for these
inflammatory diseases.
Our previous studies showed that PAF-induced increase in NF-
kB activation and IL-8 production critically required Bcl10 and
were associated with PAF-induced increase in Bcl10 gene
transcription [24]. On the other hand, LA-CS did not alter
Bcl10 mRNA and protein levels or Bcl10 promoter activity, but
attenuated PAF-induced increase in Bcl10 mRNA, protein and
promoter activity. Since LA-CS alone showed no effects on Bcl10
transcription, its effects in attenuating PAF-induced increase in I-
kB phosphorylation, NF-kB activation, and IL-8 production could
involve different mechanisms. LA-CS significantly blocked Bcl10
interactions with MALT1, but had no effect on its interactions
with CARMA3, the scaffold protein known to act upstream of
Bcl10 and MALT1. Previous studies have reported that in the T-
cell receptor pathway involving CARMA1/Bcl10/MALT1, inter-
action with MALT1 (a paracaspase) brings Bcl10 closer to IKK
complex, and that Bcl10 activates NF-kB pathway through
ubiquitination of IKKc (NEMO), the regulatory subunit of IKK
complex [29]. NEMO ubiquitination has been suggested to
represent a way to attract the IKK complex to upstream activators
and critical for canonical NF-kB activation pathway [49].
Interestingly, our current studies showed increased NEMO
ubiquitination in response to PAF treatments, whereas LA-CS
substantially attenuated this effect of PAF. These results suggest
that LA-CS could ameliorate PAF-induced intestinal inflammato-
ry responses via modulation of signaling events associated with
activation of IKK complex, rather than either the early events
following receptor activation by PAF or later events downstream
of IKK signalosome (Figure 6).
In essence, our current set of studies suggests a distinct
mechanism of functionality of probiotic-derived molecules to
combat PAF-induced intestinal inflammation at the epithelial cell
level. Our future studies to precisely define the underlying
mechanisms of LA-CS attenuation/reversal of PAF-induced
inflammatory cascade will further increase our understanding of
molecular basis of these effects in ameliorating intestinal inflam-
mation. Further, molecular characterization of the LA-secreted
Figure 3. L. acidophilus culture supernatant attenuates PAF-
induced I-kB phosphorylation and IL-8 production. (A) Phospho-
I- kB levels, as measured by ELISA, in total lysates prepared from control
or PAF 6 LA-CS-treated NCM460 cells (n = 3, *P,0.05); (B) IL-8 level as
measured by ELISA, in the spent media of control or PAF 6 LA-CS-
treated NCM460 cells (n = 3, *P,0.05).
doi:10.1371/journal.pone.0075664.g003
Probiotics Counteract PAF-Induced Inflammation
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soluble factors mediating these effects will be of great clinical
significance for the management of IBD and/or NEC.
Materials and Methods
Materials, reagents and antibodies
PAF (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) was ob-
tained from Sigma-Aldrich (St. Louis, MO). Antibodies specific for
Bcl10 (Cat# sc-13153), CARMA3 (Cat# sc-47826), MALT1
(Cat# sc-46677) and NF-kB p65 (Cat# sc-8008) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell lines, Cell culture and Treatments
The human colonic epithelial cell line NCM460, derived from
normal colonic mucosa, was grown in M3:10 medium (INCELL,
St. Antonio, TX) and maintained at 37uC in a humidified, 5%
CO2 environment. Caco-2 cells were maintained in DMEM with
4.5 g/L glucose, 50 kU/L penicillin, 5 mg/L streptomycin, and
20% fetal bovine serum. For experiments, confluent cells in cell
culture flasks were trypsinized and seeded into 24-well plates at a
cell density of 26104 cells/ml. At 60–70% confluency, cells were
used for treatments. Serum was reduced to 1% for overnight
before treatments and also during the treatments.
Bacterial culture and preparation of conditioned medium
The following probiotic Lactobacillus species, with strain numbers
given in parentheses, were obtained from American Type Culture
Collection (ATCC): L. acidophilus (4357), L. rhamnosus (53103), L.
plantarum (14917) and L. casei (393). They were grown in Mann-
Rogosa-Sharpe broth (Difco) for 24 h at 37uC without shaking.
The overnight culture was centrifuged at 3000 x g for 10 min at
4uC. The supernatant, filtered through a 0.22-mm filter (Millex,
Millipore) to sterilize and remove all bacterial cells, was designated
as conditioned medium (CS). For treating the cells with live
bacteria, the bacterial pellet was washed with DMEM/F-12 media
(Invitrogen) containing 5 mg/L mannose and resuspended in the
same media.
Treatment of cells
NCM460 or Caco-2 cells grown on 24-well plates to 60–70%
confluency were pre-treated for 6 h either with live bacteria
suspended in DMEM/F-12 media (0.56107 CFU per well) or with
CM diluted 1:10 in the same media. The 1:10 dilution was chosen
to obtain the optimal effect and at the same time to avoid adverse
effects of long-term incubation on cell viability as observed with
lesser dilutions (1:2 or 1:5). For subsequent co-incubation with or
without PAF for 24 h, the CFU of live bacteria used was reduced
to 0.56106 per well whereas CS was used at the same dilution
(1:10). Changes of pH towards acidic range upon addition of
culture supernatant to DMEM/F12 were normalized with 0.5N
NaOH before incubation.
RNA extraction and real-time RT-PCR
The total RNA from NCM460 cells was prepared using RNeasy
Mini Kit (Qiagen, Valencia, CA) according to manufacturer’s
instructions. An equal amount of RNA for each sample was
reverse-transcribed and amplified in a one-step reaction using
Brilliant SYBR Green QRT-PCR master mix kit (Stratagene, La
Jolla, CA) and using Mx 3000 (Stratagene). The gene specific
primers for human Bcl10 (59-39), were, forward: AAGGTCTG-
GACACCCTTGTT and reverse: ACAGTGGATGCCCT-
CAGTTT. The quantification of the amplification was expressed
Figure 4. L. acidophilus culture supernatant does not alter Bcl10 expression but attenuates PAF-induced increase in Bcl10
expression in IECs. (A) relative levels of Bcl10 mRNA in control or PAF6 LA-CS-treated NCM460 cells measured by real-time RT-PCR as described in
Methods (n = 3, *P,0.05); (B) Bcl10 protein levels measured by ELISA in control or PAF 6 LA-CS-treated NCM460 cells (n = 3, *P,0.05); (C)
representative blot (n = 3) of Bcl10 protein levels measured by immunoblotting (upper panel) in control or PAF 6 LA-CS-treated Caco-2 cells and
densitometric analysis of the relative band intensities (lower panel); (D) Bcl10 promoter activity in control or PAF 6 LA-CS-treated Caco-2 cells (n = 4,
*P,0.05).
doi:10.1371/journal.pone.0075664.g004
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as a ratio of 2DCt-Bcl10/2DCt-b-actin, where DCt-Bcl10 and DCt-b-
actin represent the difference between the threshold cycles of
amplification of Bcl10 and b-actin.
Immunoblotting
Proteins in the NCM460 or Caco-2 cell lysates were separated
by SDS-PAGE on an 8% gel. Proteins were transferred to a
nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ)
and probed with the Bcl10 antibody. Immunoreactive bands were
visualized using the ECL detection kit (Amersham).
Co-immunoprecipitation
Control NCM460 cells and cells treated with PAF, LA-CM
with or without PAF were washed in cold PBS and lysed in a lysis
buffer [20 mM Tris pH 7.5, 150 mM NaCl, 1% TritonX-100,
1 mM EDTA, 30 mM NaF, 2 mM sodium pyrophosphate and
1X protease inhibitor cocktail (Roche)]. The cell lysates were
pre-cleared with protein A/G plus-agarose (Santa Cruz) and then
incubated with anti-CARMA3 or anti-MALT1 antibodies at 4uC
for 16 h followed by incubation with protein A/G plus-agarose for
5 h. The agarose beads were collected by centrifugation, washed 4
times with lysis buffer and heated to 95uC for 5 min after adding
Laemmli buffer. The resulting immunoprecipitates were separated
by SDS-PAGE and probed with anti-Bcl10 antibody in immuno-
blotting.
Preparation of nuclear extract and measurement of p65
Nuclear extracts from control and treated NCM460 or Caco-2
cells were prepared using the nuclear extraction kit from Active
Motif following the manufacturer’s protocol as described earlier by
us [26]. NF-kB activation was assessed by measuring levels of
nuclear p65 by oligonucleotide-based ELISA as previously
described by us [26], or by immunoblotting with anti-p65
antibody.
NF-kB activity
NF-kB activation in response to PAF with or without pre-
incubation and co-incubation with LA-CM was measured by NF-
kB-Luciferase reporter assay as described earlier [24]. Briefly,
NCM460 or Caco-2 cells were transfected with p-NF-kB-Luc
(Clontech, CA) using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA). This plasmid contains NF-kB binding consensus
element upstream of luciferase reporter gene. Twenty-four hours
after transfection, cells were treated with PAF (10 mM) with or
without pre- and co-treatments with LA-CM for another 24 h.
Luciferase assays were performed and results were expressed as
RLU/mg protein.
ELISA for Bcl10
The levels of Bcl10 were determined by a solid-phase sandwich
ELISA, as previously developed by us [50].
ELISA for IL-8
The secretion of IL-8 in the spent media of control and treated
cells was measured by DuoSet ELISA kit for human IL-8 (R&D
Systems, Minneapolis, MN), according to the manufacturer’s
instructions as described previously by us [24].
Measurement of Bcl10 promoter activity
A 1310 bp fragment of the 59-untranslated region (p-Bcl1310) of
Bcl10 gene cloned earlier [24] into the pGL2 reporter plasmid
(Promega, Madison, WI) was transfected into Caco-2 cells were
using Lipofectamine 2000 (Invitrogen). Twenty-four h after
transfection, cells were treated with PAF for an additional 24 h
period. Subsequently, promoter activity was determined by
measuring luciferase activity and normalizing with the corre-
sponding b-galactosidase activity, according to the procedure
described previously [24].
Ubiquitination of IKK-c
Caco-2 cells were transfected with pcDNA3 expression vectors
encoding Myc-tagged IKKc and HA-tagged ubiquitin (kind gifts
from PC Lucas of the University of Michigan Medical School,
Ann Arbor, MI) and then treated with PAF and/or LA-CS as
described above. After immunoprecipitating the IKKc from the
cell lysate with anti-Myc antibody (Santa Cruz, CA), the protein
was assayed for ubiquitination by Western blotting with anti-HA
antibody (Santa Cruz, CA).
Figure 5. L. acidophilus culture supernatant attenuates PAF-
induced Bcl10 interaction with MALT1 and ubiquitination of
IKKc (NEMO). (A) Cell lysates of control or PAF 6 LA-CS-treated
NCM460 cells, containing equal amounts of proteins, were used to
immunoprecipitate (IP) MALT1 with anti-Bcl10 antibody. Immunopre-
cipitates were subjected to SDS-PAGE and probed with anti-MALT1
antibody in immunoblotting (IB). After stripping with 0.2N NaOH, blots
were re-probed with anti-Bcl10 antibody; upper panel: representative
blot of 3 independent experiments; lower panel: densitometric analysis
of relative band intensities; (B) Caco-2 cells co-transfected with
expression vectors encoding pcDNA3-IKKc-Myc and pcDNA3-ubiqui-
tin-HA were untreated or treated with PAF 6 LA-CS as described in
Methods. After purification by anti-Myc antibody immunoprecipitation,
the IKKc protein was assayed for ubiquitination by Western blotting
with anti-HA antibody.
doi:10.1371/journal.pone.0075664.g005
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Statistical analyses
The data presented are mean 6 SEM of 3–4 independent
experiments. Difference between controls versus various treat-
ments was analyzed using one-way ANOVA, with Dunnett’s
multiple comparison tests for repeated comparisons to the control.
Differences were considered significant at P,0.05.
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